RxDoctor Payments Data

James Fretwell, MD

Family Medicine · Longmont, CONPI 1053331603

Payments from drug & device makers

$2,897in general payments, 2019–2025

Across 15 payments — averaging $193.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$2K
  • Amgen$203
  • Kowa Pharmaceuticals America, Inc.$127
  • Esperion Therapeutics, Inc.$116
  • Idorsia Pharmaceuticals US Inc$114
  • Novo Nordisk$104
  • plus $257 from 6 others

What the payments were for

  • Consulting fees$1,85264%
  • Food & beverage$1,03336%
  • Education$120%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,897 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$132,732
Medicare patients
267
Services billed
1,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$73,755
TrulicityDulaglutide44$54,796
FarxigaDapagliflozin Propanediol34$37,872
OzempicSemaglutide38$37,429
JardianceEmpagliflozin28$33,069
JanuviaSitagliptin Phosphate13$20,440
MounjaroTirzepatide19$19,332
XareltoRivaroxaban12$15,194
MyrbetriqMirabegron19$13,835
LinzessLinaclotide12$12,050
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$10,330
InvokanaCanagliflozin13$7,574
Atorvastatin Calcium551$4,752
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,948
Levothyroxine Sodium391$3,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$13$74,12863 claims
AstraZenecaFarxiga$57$37,87234 claims
Novo NordiskOzempic$104$37,42938 claims
AbbVieLinzess$79$12,05012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Longmont

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →